Shots:
- Co-Diagnostics’ JV CoSara has received CDSCO’s clearance to manufacture and sell its Saragene COVID-19 2-gene multiplex RT-PCR test as an IVD, intended for the qualitative detection of the SARS-CoV-2 virus
- The kit leverages CoPrimer technology & is based on a test originally designed by Co-Diagnostics, who secured CE marking for its Logix Smart SARS-CoV-2 multiplex test in Feb’2020
- To identify the virus presence, both the tests target two gene markers of the SARS-CoV-2 genome i.e. RdRp and E-gene. Additionally, CoSara prior received CDSCO’s approval for RT-PCR tests for mycobacterium tuberculosis, malaria, hepatitis B & C and HPV to be manufactured & sold as IVDs in India
Click here to read full press release/ article | Ref: Co-Diagnostics | Image: Co-Diagnostics
The post CoSara Receives CDSCO’s Approval for its Saragene COVID-19 2-Gene Multiplex Test first appeared on PharmaShots.
